Wall Street Zen Downgrades Soleno Therapeutics (NASDAQ:SLNO) to Hold

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other equities research analysts have also recently weighed in on the company. Wolfe Research set a $60.00 price target on Soleno Therapeutics in a report on Monday, January 12th. Zacks Research cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research note on Tuesday, January 13th. TD Cowen reduced their price target on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $120.00 price objective (up from $110.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.38.

Soleno Therapeutics Trading Up 2.6%

Shares of SLNO stock opened at $39.07 on Friday. The company has a market capitalization of $2.02 billion, a P/E ratio of 169.88 and a beta of -3.16. Soleno Therapeutics has a 12-month low of $32.63 and a 12-month high of $90.32. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The firm has a 50-day moving average price of $42.63 and a 200 day moving average price of $53.13.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Research analysts forecast that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of Soleno Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Soleno Therapeutics in the 2nd quarter valued at about $25,000. Danske Bank A S acquired a new position in Soleno Therapeutics in the third quarter valued at approximately $27,000. Global Retirement Partners LLC lifted its holdings in Soleno Therapeutics by 519.0% in the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after buying an additional 519 shares during the period. Aster Capital Management DIFC Ltd bought a new position in Soleno Therapeutics in the third quarter valued at approximately $37,000. Finally, Nisa Investment Advisors LLC grew its holdings in Soleno Therapeutics by 287.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after acquiring an additional 400 shares during the period. 97.42% of the stock is owned by institutional investors.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Earnings beat and profitability: Soleno reported Q4 2025 EPS of $0.80 (vs. $0.64 consensus) and revenue of $91.73M (vs. $88.55M), and management highlighted achieving profitability — the core reason investors are bidding the stock up. Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Full earnings/transcript availability: Multiple transcripts and call write-ups (Seeking Alpha, Yahoo) give investors detailed color on guidance, margins and cash flow — useful for conviction but not immediate catalysts. Q4 2025 Earnings Call Transcript Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo cut its price target slightly from $114 to $110 but kept an Overweight rating — this is a modest headwind but still signals strong upside from analysts. Wells Fargo price-target note
• Negative Sentiment: TD Cowen substantially lowered its target (from $120 to $85) despite maintaining a Buy rating — the larger cut adds downward pressure to headline analyst sentiment and may temper the rally. TD Cowen price-target change
• Negative Sentiment: Near-term volatility / profit-taking explained: Coverage and commentary note a sharp intraday decline (reported as ~10.8% in one write-up) after the earnings run-up — investors appear to be re‑rating the name on guidance details, forward EPS expectations, and valuation. Why SLNO Stock Is Down 10.80%

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.